Healthcare / BiotechnologyNYSE American
$1.87
-0.27 (-12.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-7.3M · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$83M
P/E
N/A
•EV/EBITDA
N/A
•ROE
471.7%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-28.8M · FCF $-14.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-28.8M | $-28.8M | $-8.9M | $-7.8M | $-6.3M |
| EBITDA | $-28.4M | $-28.4M | $-6.8M | $-4.3M | $-4.4M |
| EPS | — | — | -1.28 | -0.38 | -0.32 |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | -0.61 | -0.59 |
| Current Ratio | 0.05 | 0.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-14.7M | $-14.7M | $-7.3M | $-3.0M | $-3.8M |
| Returns | |||||
| ROE | 471.7% | 471.7% | 271.9% | 32.4% | 35.6% |
| Growth & Yield | |||||
| EPS Growth | — | — | -233.0% | -20.8% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+22.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.28 → n/d
Residual
+22.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.